

I. Amendments to the Claims

This listing of claims shall replace all prior versions, and listings, of claims in the application.

Listing of claims

Claims 1-74 (canceled)

Claim 75. (currently amended): A ~~composition~~ dosage form comprising:
particles comprising

(a) a therapeutically active agent consisting essentially of an opioid antagonist
and

(b) means for sequestering the opioid antagonist ~~when the composition is orally~~
administered

such that the opioid antagonist is substantially not released when the dosage form is orally administered intact, as compared to the dosage form that has been tampered with.

Claim 76. (currently amended): The ~~composition~~ dosage form of claim 75, wherein the means for sequestering comprises a layer comprising a hydrophobic material.

Claim 77. (currently amended): The ~~composition~~ dosage form of claim 75, wherein the means for sequestering comprises from about 93% to about 98% of a hydrophobic material by weight of the composition.

Claim 78. (currently amended): The ~~composition~~ dosage form of claim 75, wherein the opioid antagonist is naltrexone, naloxone, nalmeferene, cyclazacine, levallorphan, a pharmaceutically acceptable salt or a mixture thereof.

Claim 79. (new): The dosage form of claim 75, wherein the ratio of the amount of antagonist released from said composition after tampering to the amount of said antagonist released from said intact composition is about 4:1 or greater, based on the in-

vitro dissolution at 1 hour of said composition in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37° C.

Claim 80. (new): The dosage form of claim 75, further comprising an opioid agonist in a releasable form, which is separate from said particles comprising a therapeutically active agent consisting essentially of an opioid antagonist.

Claim 81. (new): The dosage form of claim 80 which provides immediate release of said opioid agonist when the composition is orally administered.

Claim 82. (new): The dosage form of claim 80 which provides sustained release of said opioid agonist when the composition is orally administered.

Claim 83. (new): The dosage form of claim 75 which does not pose a risk of precipitation of withdrawal in opioid tolerant or dependent patients when the dosage form is orally administered intact.

Claim 84. (new): The dosage for of claim 75, wherein the opioid antagonist is not bioavailable when the dosage form is administered intact but is bioavailable when the dosage form is tampered with.

Claim 85. (new): The dosage form of claim 75, wherein said tampering is by means selected from the group consisting of crushing, shearing, grinding, chewing and dissolution in a solvent in combination with heating.

Claim 86. (new): The dosage form of claim 75, wherein said tampering is by crushing.